The combined prophylactic strategy of sodium bicarbonate plus N-acetylsyteine (NAC) seems to be effective in preventing contrast induced acute kidney injury (CI-AKI) in patients at low-to-medium risk. However, in patients at high and very high risk the rate of CI-AKI is still high. In this subset of patients the anticipated advantages of the RenalGuard(tm) System should be investigated. The RenalGuard(tm) System (PLC Medical Systems, Inc., Franklin, MA, USA) is a real-time measurement and real time matched fluid replacement device designed to accommodate the RenalGuard therapy, which is based on the theory that creating and maintaining a high urine output is beneficial by allowing a quick elimination of contrast media, and, therefore, reducing its toxic effects.

Briguori, C., Visconti, G., Ricciardelli, B., Condorelli, G., Airoldi, F., De Micco, F., et al. (2011). Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design. EUROINTERVENTION, 6(9), 1117-1117-22, 7 [10.4244/EIJV6I9A194].

Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design

SANGIORGI, GIUSEPPE;
2011-04-01

Abstract

The combined prophylactic strategy of sodium bicarbonate plus N-acetylsyteine (NAC) seems to be effective in preventing contrast induced acute kidney injury (CI-AKI) in patients at low-to-medium risk. However, in patients at high and very high risk the rate of CI-AKI is still high. In this subset of patients the anticipated advantages of the RenalGuard(tm) System should be investigated. The RenalGuard(tm) System (PLC Medical Systems, Inc., Franklin, MA, USA) is a real-time measurement and real time matched fluid replacement device designed to accommodate the RenalGuard therapy, which is based on the theory that creating and maintaining a high urine output is beneficial by allowing a quick elimination of contrast media, and, therefore, reducing its toxic effects.
apr-2011
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE
English
Con Impact Factor ISI
Renal Insufficiency; Chi-Square Distribution; Humans; Diuretics; Furosemide; Research Design; Italy; Risk Assessment; Fluid Therapy; Equipment Design; Acute Kidney Injury; Treatment Outcome; Acetylcysteine; Kidney Diseases; Triiodobenzoic Acids; Time Factors; Sodium Bicarbonate; Contrast Media; Drug Therapy, Combination; Creatinine; Glomerular Filtration Rate; Risk Factors; Chronic Disease; Radiography, Interventional; Biological Markers
Briguori, C., Visconti, G., Ricciardelli, B., Condorelli, G., Airoldi, F., De Micco, F., et al. (2011). Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design. EUROINTERVENTION, 6(9), 1117-1117-22, 7 [10.4244/EIJV6I9A194].
Briguori, C; Visconti, G; Ricciardelli, B; Condorelli, G; Airoldi, F; De Micco, F; Focaccio, A; Giannone, R; Golia, B; Quintavalle, C; Caiazzo, G; Briguori, C; Zanca, C; Iaboni, M; Rivera, N; Tavano, D; Bertoli, S; Staine, T; Valgimigli, M; Ferrari, R; Monti, M; Sangiorgi, G; Lambertini, S
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/107561
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 15
social impact